Fig. 1

MSLN-targeted therapy strategies. a, the precursor protein is cleaved into two products, i.e. soluble protein MPF and GPI-anchored membrane protein MSLN; b, anti-MSLN antibody derived scFv, Fab, or intact/modified antibody are conjugated with the effector molecules (inhibitor or toxin) and induce cell death after binding to tumor cells; c, the binding of amatuximab to MSLN expressed on tumor cell membrane leads to ADCC; d, HPN536 directs T cells to kill tumor cells expressing MSLN; e, cancer vaccines arouse tumor specific immune response; f, the T cells are engineering to express CAR and redirected to tumor cells